3 recruiting, 2 active not recruiting, 2 completed. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 3, Active not recruiting 2, Completed 2 |
Follow Polycythemia Vera (PV): new trials by email Literature Review of Polycythemia Vera (PV) trials Research Report on Polycythemia Vera (PV)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Ropeg-Interferon in People With Polycythemia Vera Ropeginterferon - Polycythemia Vera (PV), JAK2 Mutation | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 55 | 2026-10-30 | 2026-11-03 |
| Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera Flonoltinib 75mg, Flonoltinib 100mg, Flonoltinib 125mg - Polycythemia Vera (PV) | Phase 2 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 60 | 2025-09-23 | 2026-08-14 |
| A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) DISC-3405 - Polycythemia Vera (PV) | Phase 2 | Active not recruiting | Disc Medicine, Inc | 60 | 2025-08-12 | 2026-11-02 |
| MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial Methotrexate (MTX) - Polycythemia Vera (PV), Essential Thrombocythemia (ET) | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 54 | 2024-10-02 | 2025-12-17 |
| Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients Apixaban 2.5 MG Oral Tablet [ELIQUIS], Aspirin 81 mg - Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET) | Phase 2 | Completed | Ottawa Hospital Research Institute | 44 | 2021-02-17 | 2024-05-29 |
| Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply P1101, Low-dose aspirin, Phlebotomy - Polycythemia Vera (PV) | Phase 2 | Completed | PharmaEssentia Japan K.K. | 29 | 2019-12-20 | 2025-09-15 |
| The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia Ruxolitinib, BAT - Polycythemia Vera (PV), Essential Thrombocythemia (ET) | Phase 2 | Active not recruiting | RWTH Aachen University | 207 | 2015-10-01 | 2026-08-13 |
Polycythemia Vera (7) · Thrombocythemia, Essential (3) · Myeloproliferative Disorders (2) · Primary Myelofibrosis (2) · Venous Thromboembolism (1)
Bone Marrow Diseases (7) · Bone Marrow Neoplasms (7) · Hematologic Diseases (7) · Hematologic Neoplasms (7) · Hemic and Lymphatic Diseases (7) · Neoplasms (7) · Neoplasms by Site (7) · Myeloproliferative Disorders (5) · Blood Coagulation Disorders (3) · Blood Platelet Disorders (3) · Hemorrhagic Disorders (3) · Thrombocytosis (3) · Cardiovascular Diseases (1) · Embolism and Thrombosis (1) · Thromboembolism (1)
Aspirin (2) · Drug Evaluation (1) · Methotrexate (1) · Phlebotomy (1) · Tablets (1) · apixaban (1) · ruxolitinib (1)
Chengdu Zenitar Biomedical Technology Co., Ltd (1) · Disc Medicine, Inc (1) · Icahn School of Medicine at Mount Sinai (1) · Memorial Sloan Kettering Cancer Center (1) · Ottawa Hospital Research Institute (1) · PharmaEssentia Japan K.K. (1) · RWTH Aachen University (1)
United States (3) · Canada (1) · China (1) · Germany (1) · Japan (1)
Aurelien Delluc, MD, PhD (1) · John Mascarenhas (1) · Lei Zhang, Doctor (1) · Miriam Kimpton, MD (1) · Raajit Rampal, MD, PhD (1) · Steffen Koschmieder, Prof. Dr. (1) · Ting Niu, Doctor (1) · Wei Yang, Doctor (1) · Will Savage, MD PhD (1)